Waldencast’s (WALD) Obagi Medical unveils its latest innovation: Nu-Cil BioStim Scalp Serum. “In my practice, I’m seeing a rising number of patients with hair loss concerns, ranging from those with underlying hormonal contributors, such as PCOS, perimenopause, and postmenopause, to younger men aiming to maintain hair density as they age, to those with thyroid disorders or nutritional deficiencies following significant weight loss,” said Dr. Suzan Obagi, Chief Medical Officer of Obagi. “We’re excited about the launch of Nu-Cil BioStim Scalp Serum because it was designed to address these concerns. It was evaluated in a six-month, double-blind clinical study, with results showing that participants using Nu-Cil BioStim Scalp Serum experienced meaningful improvements as early as two weeks into treatment.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast Gains FDA Approval for Obagi Injectable Gel, Expanding U.S. Market Reach
- Waldencast: FDA approves Obagi saypha MagIQ injectable hyaluronic acid gel
- Waldencast Reports Strategic Growth and New Acquisitions
- Waldencast’s Strategic Positioning and Growth Potential: A Buy Rating Amidst Strategic Review and Financial Restructuring
- Waldencast price target lowered to $3 from $4 at Telsey Advisory